Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 9 May 2025 PM
A Phase 2 study has generated more evidence in favour of using GSK’s Jemperli to treat mismatch repair-deficient (dMMR) cancers, with data suggesting it can trigger complete tumour clearance, particularly in rectal cancer.
Jemperli was first approved by the TGA in 2022 in combination with carboplatin and paclitaxel for adults with primary advanced or recurrent endometrial cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.